



# Prior Authorization Request Form

## Tolvaptan (Jinarc®) / Autosomal dominant polycystic kidney disease (ADPKD)

### DECLARATION OF THE INSURED PERSON

#### Section 1: Information about the participant and the patient

Name of participant	Policy	Certificate	Name of employer
Name of patient	Date of birth	Telephone	
Address (number and street name)	Town/City	Province	Postal code

#### Section 2: Other prescription drug insurance policies

Do you have other prescription drug insurance?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
If so, please answer the following:			
What type of plan is it?	<input type="checkbox"/> Private	<input type="checkbox"/> Public	
Have you ever submitted a claim <b>FOR THIS DRUG</b> to the other insurer?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
What is the status of the claim?	<input type="checkbox"/> Accepted	<input type="checkbox"/> Refused	<input type="checkbox"/> Under review
Did this insurer ask you to complete a prior authorization request?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
If so, what is the status of the prior authorization request?	<input type="checkbox"/> Accepted	<input type="checkbox"/> Refused	<input type="checkbox"/> Under review

Please enclose acceptance or refusal documents, if applicable

#### Section 3: Authorization to disclose personal information

I certify that the information in this prior authorization request is complete, accurate and true.

I authorize physicians and other health care professionals, medical, paramedical or clinical institutions, care coordinators, members of SSQ's Preferred Pharmacy Network (outside Quebec only) and any public or parapublic organization, including Régie de l'assurance maladie du Québec, to disclose to SSQ, Life Insurance Company Inc. (SSQ) any of my personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request. I hereby waive their confidentiality obligation and authorize them to disclose the requested information to SSQ. In addition, I authorize SSQ to disclose to the previously named third parties any of my personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request.

Photocopies of this document have the same value as the original.

Signature of patient (parent/legal guardian)

Date

#### IMPORTANT:

All correspondence concerning this form will be sent to the address indicated in the participant's file.

Send us this duly completed form by mail or by fax to: 1-855-453-3942.

Telephone: 418-651-2588/1-800-380-2588 – Fax: 1-855-453-3942  
 Address: 2525 Laurier Blvd, P.O. Box 10500, Quebec City, QC G1V 4H6  
 ssq.ca

**DECLARATION OF THE PHYSICIAN****Section 4: Information about the prescribing physician**

\_\_\_\_\_  
 Name of physician Specialty License no.  
 \_\_\_\_\_  
 Telephone Fax

I hereby certify that the information in this request is complete, true and accurate.

\_\_\_\_\_  
 Signature of physician Date

**Section 5: Drug covered by the authorization**

Drug name	Pharmaceutical form	Strength	Dosage
Jinarc®	Tablets		Dose: _____ Frequency of administration: _____

**Type of request**     First request     Continuation of treatment  
 Complete section 6    Complete section 7  
 Also complete section 6 if this is the first authorization requested from SSQ

**Section 6: Clinical information (first request)****Diagnosis**

- Autosomal dominant polycystic kidney disease (ADPKD)  
 Other, specify: \_\_\_\_\_

**Provide the following information:**

Total kidney volume : \_\_\_\_\_ mL  
 Kidney length : \_\_\_\_\_ cm  
 Current estimated glomerular filtration rate (eGFR) : \_\_\_\_\_ mL/min/1,73 m<sup>2</sup>  
 Mayo Clinical Classification:     1A     1B     1C     1D     1E  
 Check and complete if applicable:  
 Decline in eGFR over the last year, please specify observed decrease : \_\_\_\_\_ mL/min/1,73 m<sup>2</sup>/year  
 Total renal volume increase of more than 5% in the last year

**Section 7: Clinical information (continuation of treatment)****Information necessary to evaluate the response to treatment**

The drug covered by the present authorization request was first taken on: \_\_\_\_\_

**Most recent evaluation**

Date: \_\_\_\_\_  
 Estimated glomerular filtration rate: \_\_\_\_\_ mL/min/1.73 m<sup>2</sup>

**Section 8: Additional information**

Lined area for providing additional information, consisting of multiple horizontal lines.